These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 31747514)
1. Assessing Peptide Binding to MHC II: An Accurate Semiempirical Quantum Mechanics Based Proposal. Ortiz-Mahecha CA; Bohórquez HJ; Agudelo WA; Patarroyo MA; Patarroyo ME; Suárez CF J Chem Inf Model; 2019 Dec; 59(12):5148-5160. PubMed ID: 31747514 [TBL] [Abstract][Full Text] [Related]
2. MHCBI: a pipeline for calculating peptide-MHC binding energy using semi-empirical quantum mechanical methods with explicit/implicit solvent models. Ortiz-Mahecha CA; Agudelo WA; Patarroyo MA; Patarroyo ME; Suárez CF Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 33979434 [TBL] [Abstract][Full Text] [Related]
3. Peptide linkage to the α-subunit of MHCII creates a stably inverted antigen presentation complex. Schlundt A; Günther S; Sticht J; Wieczorek M; Roske Y; Heinemann U; Freund C J Mol Biol; 2012 Oct; 423(3):294-302. PubMed ID: 22820093 [TBL] [Abstract][Full Text] [Related]
4. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism. Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347 [TBL] [Abstract][Full Text] [Related]
5. The Utility of Supertype Clustering in Prediction for Class II MHC-Peptide Binding. Shen WJ; Zhang X; Zhang S; Liu C; Cui W Molecules; 2018 Nov; 23(11):. PubMed ID: 30463372 [TBL] [Abstract][Full Text] [Related]
6. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Ghosh P; Amaya M; Mellins E; Wiley DC Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400 [TBL] [Abstract][Full Text] [Related]
7. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules. Hitzel C; Koch N Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221 [TBL] [Abstract][Full Text] [Related]
8. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study. Yaneva R; Springer S; Zacharias M Biopolymers; 2009 Jan; 91(1):14-27. PubMed ID: 18767126 [TBL] [Abstract][Full Text] [Related]
9. Self and foreign peptides interact with intact and disassembled MHC class II antigen HLA-DR via tryptophan pockets. Kropshofer H; Bohlinger I; Max H; Kalbacher H Biochemistry; 1991 Sep; 30(38):9177-87. PubMed ID: 1892827 [TBL] [Abstract][Full Text] [Related]
10. Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships. Hattotuwagama CK; Doytchinova IA; Flower DR Methods Mol Biol; 2007; 409():227-45. PubMed ID: 18450004 [TBL] [Abstract][Full Text] [Related]
11. Clip binds to HLA class II using methionine-based, allele-dependent motifs as well as allele-independent supermotifs. Geluk A; Van Meijgaarden KE; Drijfhout JW; Ottenhoff TH Mol Immunol; 1995 Sep; 32(13):975-81. PubMed ID: 7477003 [TBL] [Abstract][Full Text] [Related]
12. Binding interactions between peptides and proteins of the class II major histocompatibility complex. McFarland BJ; Beeson C Med Res Rev; 2002 Mar; 22(2):168-203. PubMed ID: 11857638 [TBL] [Abstract][Full Text] [Related]
13. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding. Murthy VL; Stern LJ Structure; 1997 Oct; 5(10):1385-96. PubMed ID: 9351812 [TBL] [Abstract][Full Text] [Related]
14. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM. Verreck FA; Fargeas CA; Hämmerling GJ Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327 [TBL] [Abstract][Full Text] [Related]
15. Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. Natarajan SK; Assadi M; Sadegh-Nasseri S J Immunol; 1999 Apr; 162(7):4030-6. PubMed ID: 10201925 [TBL] [Abstract][Full Text] [Related]
16. Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif. Zhu Y; Rudensky AY; Corper AL; Teyton L; Wilson IA J Mol Biol; 2003 Feb; 326(4):1157-74. PubMed ID: 12589760 [TBL] [Abstract][Full Text] [Related]
17. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules. Malcherek G; Gnau V; Jung G; Rammensee HG; Melms A J Exp Med; 1995 Feb; 181(2):527-36. PubMed ID: 7836909 [TBL] [Abstract][Full Text] [Related]
18. A practical guide to structure-based prediction of MHC-binding peptides. Ranganathan S; Tong JC Methods Mol Biol; 2007; 409():301-8. PubMed ID: 18450010 [TBL] [Abstract][Full Text] [Related]
19. Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. Sato AK; Zarutskie JA; Rushe MM; Lomakin A; Natarajan SK; Sadegh-Nasseri S; Benedek GB; Stern LJ J Biol Chem; 2000 Jan; 275(3):2165-73. PubMed ID: 10636922 [TBL] [Abstract][Full Text] [Related]
20. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Chicz RM; Urban RG; Lane WS; Gorga JC; Stern LJ; Vignali DA; Strominger JL Nature; 1992 Aug; 358(6389):764-8. PubMed ID: 1380674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]